These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 23440329)
1. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma. Yco LP; Geerts D; Koster J; Bachmann AS Int J Oncol; 2013 Apr; 42(4):1408-16. PubMed ID: 23440329 [TBL] [Abstract][Full Text] [Related]
2. Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation. Geerts D; Wallick CJ; Koomoa DL; Koster J; Versteeg R; Go RC; Bachmann AS Clin Cancer Res; 2007 Nov; 13(21):6312-9. PubMed ID: 17975142 [TBL] [Abstract][Full Text] [Related]
3. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121 [TBL] [Abstract][Full Text] [Related]
4. Subcellular distribution and expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in malignant glioma: Influence on cell survival and migration. Borsics T; Lundberg E; Geerts D; Koomoa DL; Koster J; Wester K; Bachmann AS Cancer Sci; 2010 Jul; 101(7):1624-31. PubMed ID: 20412121 [TBL] [Abstract][Full Text] [Related]
5. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome. Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668 [TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma. Chen ST; Jeng YM; Chang CC; Chang HH; Huang MC; Juan HF; Hsu CH; Lee H; Liao YF; Lee YL; Hsu WM; Lai HS Cancer Sci; 2011 Dec; 102(12):2191-8. PubMed ID: 21917080 [TBL] [Abstract][Full Text] [Related]
7. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Koomoa DL; Geerts D; Lange I; Koster J; Pegg AE; Feith DJ; Bachmann AS Int J Oncol; 2013 Apr; 42(4):1219-28. PubMed ID: 23440295 [TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma. Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394 [TBL] [Abstract][Full Text] [Related]
9. Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma. Ochiai H; Takenobu H; Nakagawa A; Yamaguchi Y; Kimura M; Ohira M; Okimoto Y; Fujimura Y; Koseki H; Kohno Y; Nakagawara A; Kamijo T Oncogene; 2010 May; 29(18):2681-90. PubMed ID: 20190806 [TBL] [Abstract][Full Text] [Related]
10. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms. Zins K; Kovatchki D; Lucas T; Abraham D Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225 [TBL] [Abstract][Full Text] [Related]
11. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression. Liu Z; Yang X; Li Z; McMahon C; Sizer C; Barenboim-Stapleton L; Bliskovsky V; Mock B; Ried T; London WB; Maris J; Khan J; Thiele CJ Cell Death Differ; 2011 Jul; 18(7):1174-83. PubMed ID: 21252912 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of mir-21, which is up-regulated during MYCN knockdown-mediated differentiation, does not prevent differentiation of neuroblastoma cells. Buechner J; Henriksen JR; Haug BH; Tømte E; Flaegstad T; Einvik C Differentiation; 2011 Jan; 81(1):25-34. PubMed ID: 20980091 [TBL] [Abstract][Full Text] [Related]
13. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma. Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575 [TBL] [Abstract][Full Text] [Related]
14. Significance of survivin mRNA expression in prognosis of neuroblastoma. Ito R; Asami S; Motohashi S; Ootsuka S; Yamaguchi Y; Chin M; Shichino H; Yoshida Y; Nemoto N; Mugishima H; Suzuki T Biol Pharm Bull; 2005 Apr; 28(4):565-8. PubMed ID: 15802787 [TBL] [Abstract][Full Text] [Related]
16. [Role and mechanism of cysteine and glycine-rich protein 2 in the malignant progression of neuroblastoma]. Zhang Y; Guo J; Zhan S; Hong E; Yang H; Jia A; Chang Y; Guo Y; Zhang X Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):495-504. PubMed ID: 38864136 [TBL] [Abstract][Full Text] [Related]
17. Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Woo CW; Tan F; Cassano H; Lee J; Lee KC; Thiele CJ Pediatr Blood Cancer; 2008 Feb; 50(2):208-12. PubMed ID: 17420990 [TBL] [Abstract][Full Text] [Related]
18. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis. Yu Y; Chen F; Jin Y; Yang Y; Wang S; Zhang J; Chen C; Zeng Q; Han W; Wang H; Guo Y; Ni X Acta Biochim Pol; 2020 Dec; 67(4):595-603. PubMed ID: 33326736 [TBL] [Abstract][Full Text] [Related]
19. Expression profile of PRAF2 in the human brain and enrichment in synaptic vesicles. Koomoa DL; Go RC; Wester K; Bachmann AS Neurosci Lett; 2008 May; 436(2):171-6. PubMed ID: 18395978 [TBL] [Abstract][Full Text] [Related]
20. [Study on MYCN gene amplification and CD44 expression in neuroblastoma]. Hu HL; He LJ Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]